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Subjects with baseline mini-mental state examination 
(MMSE) scores of mild to moderate Alzheimer’s disease 
(AD) were treated with algal docosahexaenoic acid 
(DHA, 2,000  mg/day) for 18 months in a randomized 
double-blind placebo-controlled trial to determine the 
impact on AD progression. Th   e rationale for testing DHA 
was strong. It is enriched in neuronal membranes but 
depleted in AD. Multiple epidemiological studies report 
diets rich in ﬁ  sh or DHA reduce AD risk, most clearly in 
non-apolipoprotein E4 (ApoE4) carriers [1]. Preclinical 
studies with DHA have not yet modeled ApoE isoform 
pharmacogenomics, but mice transgenic for familial 
dominant AD mutations that elevate β-amyloid (Aβ) 
production are vulnerable to dietary DHA depletion. 
DHA and its metabolites pleiotropically impact Aβ pro-
duc  tion, insulin/neurotrophic signaling, tau kinase 
activa  tion and synaptic plasticity [1]. Although DHA had 
no impact on cognitive or functional decline based on 
intent to treat AD, in non-ApoE4 carriers, DHA supple-
mentation appeared to reduce declines in MMSE and 
Alzheimer Disease Assessment Scale-Cognitive (ADAS-
Cog). Th  is commentary discusses the trial’s results and 
important questions raised, including the need for 
optimization of dose and antioxidant combinations and 
whether there should be further investigation of the 
impact of DHA on slowing cognitive decline in non-
ApoE4 carriers. Perhaps a larger issue is whether agents 
directed at amyloid or tau pathology or associated with 
reduced AD risk should be translated with an intent-to-
treat earlier disease stages rather than mild to moderate 
AD.
Th   e randomized trial of DHA for AD provides evidence 
that DHA supplementation provides no general beneﬁ  t 
to AD patients, including no overall impact on Clinical 
Dementia Rating (CDR) scale, ADAS-Cog, MMSE, 
Neuropsychiatric Inventory (NPI; P = 0.11) and Activities 
of Daily Living (ADL) [2]. Th  e authors argue that DHA 
may still have potential for prevention. Th  us,  a 
fundamental question arising out of this study is the stage 
at which we should treat. First, three smaller studies 
showed an apparent beneﬁ  t from ﬁ  sh oil treatment in 
mild cognitive impairment but not in mild to moderate 
AD subjects [3-5]. With age-associated memory 
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The results of a randomized double-blind placebo-
controlled trial with docosahexaenoic acid (DHA) 
supplementation in mild to moderate Alzheimer’s 
disease (AD) published by Quinn and colleagues 
in JAMA argues against overall effi   cacy of DHA 
in slowing progression. However, certain caveats 
in the results caution against discarding DHA 
altogether, raising questions about oxidation, dosage, 
pharmacogenomics and stage of intervention. 
One potential misconception is that what works 
for prevention will slow progression in AD subjects. 
Preclinical studies with DHA supported the rationale 
for early stage intervention; and three epidemiological 
studies indicated DHA intake was associated with 
reduced risk in non-apolipoprotein E4 (ApoE4) 
carriers. Putative drugs are initially tested for impact 
on progression because prevention approaches are 
problematic. However, should a drug be discarded for 
prevention if it fails to modify progression? Consistent 
with epidemiology, DHA signifi  cantly benefi  ted two 
measures of cognition in mild to moderate non-
ApoE4 carriers. Although the results of this trial were 
overall negative, failing to modify other outcomes, this 
commentary discusses important questions raised by 
them. Should future trials pursue DHA in non-ApoE4 
carriers for slowing progression? Since in vivo oxidation 
of DHA may have adverse eff  ects, particularly in ApoE4 
patients, should preclinical and clinical studies be 
performed to optimize dose and mitigate oxidation 
before pursuing intervention or prevention trials with 
DHA? And fi  nally, should DHA be tested now for mild 
cognitive impairment or prevention?
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MIDAS (Memory Improve  ment with DHA Study) trial 
[7] found signiﬁ  cant cognitive beneﬁ  ts with DHA. While 
there have been two ﬁ  sh oil trials in unimpaired elderly in 
which no cognitive beneﬁ  ts were observed [8,9], subjects 
in both were cognitively normal at baseline, and the latter 
failed to show signiﬁ  cant cognitive decline in the placebo 
group. Th  is study argues that ﬁ  sh oil is not a cognitive 
enhancer, but does not examine disease modiﬁ  cation in 
subjects with pathology-driven memory deﬁ  cits. Second, 
animal studies report DHA/ﬁ   sh oil act on two 
pathological endpoints that plateau by mild to moderate 
stages: Aβ accumulation [10] and loss of superior cortical 
drebrin, an excitatory synaptic marker [11] (reviewed in 
[1]). Dramatic medial and superior temporal drebrin loss 
plateaus early with mild cognitive impairment by MMSE 
26 [12], so loss has already occurred in trial subjects. 
While DHA reduced both Aβ and tau pathology in 3xTg 
AD mice [13], that intervention was early (pre-
pathology). In contrast, with late post-pathology inter-
vention in human tau transgenic mice with signi  ﬁ  cant 
neuron loss, we ﬁ  nd DHA treatment is insuﬃ   cient to 
produce signiﬁ  cant cognitive and synaptic improve  ments 
(GMC and SAF, Society for Neuroscience presen  tations, 
2010). Finally, epidemiological risk factors may be 
relevant to prevention, but not necessarily to treatment. 
Animal model data with DHA support early intervention 
for primary prevention or mild cognitive impairment and 
suggest a failure to impact tangle and neuron loss driven 
deﬁ  cits at later stages.
Although the data demonstrate that DHA has no 
general beneﬁ  t for AD, a concern remains as to whether 
the key negative eﬀ  ect may be driven by the failure of 
ApoE4 subjects to respond. Since non-ApoE4 carriers 
comprise a large segment of the US (approximately 75%) 
and AD (approximately 50%) populations, whether DHA 
may slow progression in non-ApoE4 carriers is impor-
tant. Figure 3 in [2] indicates that 40% of non-ApoE4 
carriers showed signiﬁ  cant (P = 0.03) stabilization of both 
ADAS-Cog and MMSE, but not with correction for 
multiple comparisons. Th  e authors point out that three 
epidemio  logical studies showed reduced risk with ﬁ  sh 
consump  tion only in the ApoE4 non-carriers, but add 
that pharmacogenomic interaction was not seen with 
CDR, ADL or NPI. For example, NPI showed a trend 
indepen  dent of genotype, worsening less (2.93 points) in 
the DHA group than in the placebo group (5.09 points, 
P  =  0.11). Are pathogenic mechanisms impacting NPI, 
ADL, CDR and MMSE/ADAS-Cog the same? Th  us, any 
pharmacogenomic potential of DHA requires clariﬁ    cation.
For prevention or treatment, one might expect ApoE 
genotype-DHA interactions. Because ApoE4 accelerates 
pathogenesis, age-matched ApoE4 patients may have 
more intractable AD pathology. Further, one important 
target of DHA is insulin resistance [14], but drugs target-
ing insulin resistance (insulin or peroxisome proliferator-
activated receptor (PPAR)γ agonists) appears more 
eﬀ  ective at reducing cognitive deﬁ  cits in ApoE3 carriers 
than ApoE4 carriers [15]. ApoE is a major central nervous 
system lipid transport protein with isoform-dependent 
traﬃ   cking likely to impact DHA compartmentalization 
in the brain. Finally, ApoE4 increases oxidative stress, 
and with six double bonds, DHA is readily oxidized.
Th  is raises other critical issues that need to be 
addressed before pursuing a future trial: dose and oxida-
tion. Th   e authors discuss the need to investigate potential 
combinations of DHA with antioxidants in AD patients, 
given apparent beneﬁ  ts with combinations of ﬁ  sh oil and 
lutein or lipoate in small trials and with antioxidants in 
the Souvenaid trial. Oxidation of DHA to neuroprostanes 
is associated with synaptic loss. Further oxidation 
produces a toxic end-product, 4-hydroxyhexenal, that 
contributes to neuron death and defective uptake of 
glucose by neurons and glutamate by astrocytes. Clinical 
studies demonstrate that similar dosing with marine n-3 
fatty acids (polyunsaturated fatty acids with a double 
bond at the third carbon), including DHA, can deplete 
vitamin E and increase some peripheral measures of 
oxidative damage, particularly with dosing up to 
6  months [16]. Because DHA is enriched in the brain 
where oxidative damage is already increased in AD 
patients, antioxidant supplements optimized for AD 
brain appear crucial. Even though marine n-3 fatty acids 
can deplete vitamin E, high dose vitamin E (900 IU) did 
not reduce measures of lipid peroxidation in human 
plasma [17], so vitamin E supplementation is probably 
not suﬃ   cient. In mice the lipophilic phenolic antioxidant 
food additive butylhydroxytoluene attenuated measures 
of lipid peroxidation in plasma after high intake of ﬁ  sh oil 
[18]. Th  e preclinical studies with DHA in AD mouse 
models require encapsulation of DHA in the chow to 
minimize oxidation [10,11]. Also, using the US Food and 
Drug Administration’s equation to estimate the human 
equivalent doses, the clinical trial dose was three-fold 
higher than the eﬃ     cacious preclinical dose in mice 
[10,11], and twice as high as in the MIDAS trial [7], 
raising questions about whether the dose may have been 
too high, potentially exacerbating oxidative damage.
Possible cognitive beneﬁ   ts in patient subgroups 
(pharma  co  genomic or otherwise) would be strengthened 
by evidence of a biomarker response, arguing for the 
need to validate neuroimaging, cerebrospinal ﬂ  uid  or 
plasma biomarker responses in preclinical studies going 
forward. MRI was performed in a small subset of 
subjects, showing that volumentrics of the left hippo-
campus in the DHA group showed trends to be smaller 
than in the placebo group (P = 0.17), which may indicate 
brain shrinkage. In the AN1792 active Aβ vaccination, 
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drugs may only work in a subset of patients, it would be 
helpful in large studies where neuroimaging or 
cerebrospinal ﬂ  uid biomarker analysis are less feasible to 
identify likely responders with plasma biomarkers. A 
diﬃ   cult task at hand is to design future DHA or other 
trials with earlier intervention to include validated 
surrogate and/or diagnostic biomarkers that have shown 
DHA responses in animal models. For tracking adverse 
eﬀ  ects of DHA, it is important to measure blood vitamin 
E depletion and lipid peroxides (thiobarbituric acid 
reactive substances, malondialdehyde, or the speciﬁ  c 
byproduct of DHA oxidation, 4-hydroxyhexenal). 
Biomarker validation could track mechanisms and lower 
trial costs and facilitate choice of eﬃ   cacious doses before 
proceeding to longer term, more costly trials to evaluate 
conversion to AD.
Conclusion
Th  e study by Quinn and colleagues provides additional 
rationale to test DHA for prevention, with focus on non-
ApoE4 carriers, but problems with DHA dosing and 
oxidation need to be addressed (particularly if an 
antioxidant could correct a failed ApoE4 response to 
DHA). Additional preclinical studies of stage-dependent 
eﬃ   cacy and ApoE4-DHA interaction may help to clarify 
whether ApoE genotype aﬀ  ects outcomes and how this 
can be mitigated, possibly with antioxidants or non-
steroidal anti-inﬂ   ammatory drugs (NSAIDs). Beyond 
pharmacogenomic roadblocks emerging with DHA and 
other interventions, all of the epidemiology and most of 
the animal model data that have been generated are most 
relevant to early stage interventions, but have been 
translated in clinical trials in mild to moderate AD, 
potentially resulting in an intent-to-treat the wrong 
group. Th  e pre-clinical conclusions may not be wrong, 
but simply still lost in this translation.
Abbreviations
Aβ, β-amyloid; AD, Alzheimer’s disease; ADAS-Cog, Alzheimer Disease 
Assessment Scale-Cognitive; ADL, Activities of Daily Living; ApoE, 
apolipoprotein E; CDR, Clinical Dementia Rating; DHA, docosahexaenoic 
acid; MIDAS, Memory Improvement with DHA Study; MMSE, mini-mental 
state examination; MRI, magnetic resonance imaging; NPI, Neuropsychiatric 
Inventory.
Competing interests
GMC has received reimbursements from Martek Biosciences for travel and 
lectures that he has presented on DHA and as a member of their expert panel. 
SAF has no competing fi  nancial interests
Authors’ contributions
GMC and SAF made equal contributions in writing this commentary.
Author information
GMC is Associate Director of the Mary S Easton University of California, Los 
Angeles (UCLA) Alzheimer’s Disease Research Center and of the Veteran’s 
Greater Los Angeles Healthcare System, Geriatric Research Education and 
Clinical Core (GRECC). SAF is Chief of Neurogerontology at the GRECC, and 
both SAF and GMC are Professors of Medicine and Neurology at UCLA. 
GMC and SAF have contributed to the fi  eld in elucidating mechanisms in 
Alzheimer’s and developing models for translation.
Acknowledgments
We thank the Mary S Easton Alzheimer’s Drug Discovery Program and VA 
Merits for funding (SAF, GMC) and NIH R01AG13471 (GMC), NIH R01AT03008 
(GMC), NIH R01AG021795 (SAF), NIH U01AG028783 (SAF), NIH RC1AG035878 
(SAF, GMC).
Author details
1Veterans Greater Los Angeles Healthcare System, Geriatric Research 
Education and Clinical Center, 16111 Plummer St, North Hills, CA 91343, 
USA. 2Departments of Medicine and Neurology, Mary S Easton Center for 
Alzheimer’s Disease Research at UCLA, 10911 Weyburn Avenue, Suite 200 Los 
Angeles CA 90095, USA.
Published: 20 January 2011
References
1.  Cole GM, Frautschy SA: DHA may prevent age-related dementia. J Nutr 
2010, 140:869-874.
2.  Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin 
JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS: Docosahexaenoic acid 
supplementation and cognitive decline in Alzheimer disease: a 
randomized trial. JAMA 2010, 304:1903-1911.
3.  Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, 
Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J: Omega-3 fatty acid 
treatment in 174 patients with mild to moderate Alzheimer disease: 
OmegAD study: a randomized double-blind trial. Arch Neurol 2006, 
63:1402-1408.
4.  Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY: 
The eff  ects of omega-3 fatty acids monotherapy in Alzheimer’s disease 
and mild cognitive impairment: a preliminary randomized double-blind 
placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 
32:1538-1544.
5.  Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara 
M, Yoshimoto T, Guo J, Yamashima T: Dietary supplementation of 
arachidonic and docosahexaenoic acids improves cognitive dysfunction. 
Neurosci Res 2006, 56:159-164.
6.  Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM: 
Cognitive fi  ndings of an exploratory trial of docosahexaenoic acid and 
lutein supplementation in older women. Nutr Neurosci 2008, 11:75-83.
7.  Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N 
Jr, Stedman M, Investigators M: Benefi  cial eff  ects of docosahexaenoic acid 
on cognition in age-related cognitive decline. Alzheimers Dement 2010, 
6:456-464.
8.  Van de Rest O, Geleijnse J, Kok F, van Staveren W, Dullemeijer C, OldeRikkert 
M, Beekman A, de Groot L: Eff  ect of fi  sh oil on cognitive performance in 
older subjects: a randomized controlled trial. Neurology 2008, 71:430-438.
9.  Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, Hardy P, Holder GE, 
Knight R, Letley L, Richards M, Uauy R: Eff  ect of 2-y n-3 long-chain 
polyunsaturated fatty acid supplementation on cognitive function in 
older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 
2010, 91:1725-1732.
10.  Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, 
Cole GM: A diet enriched with the omega-3 fatty acid docosahexaenoic 
acid reduces amyloid burden in an aged Alzheimer mouse model. 
J Neurosci 2005, 25:3032-3040.
11.  Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, 
Salem N Jr, Ashe KH, Frautschy SA, Cole GM: Docosahexaenoic acid protects 
from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 
2004, 43:633-645.
12.  Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ: Diff  erential expression of 
synaptic proteins in the frontal and temporal cortex of elderly subjects 
with mild cognitive impairment. J Neuropathol Exp Neurol 2006, 65:592-601.
13.  Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, 
LaFerla FM: Dietary docosahexaenoic acid and docosapentaenoic acid 
ameliorate amyloid-beta and tau pathology via a mechanism involving 
presenilin 1 levels. J Neurosci 2007, 27:4385-4395.
14.  Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, 
Frautschy and Cole Alzheimer’s Research & Therapy 2011, 3:2 
http://alzres.com/content/3/1/2
Page 3 of 4Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM: Beta-amyloid oligomers 
induce phosphorylation of tau and inactivation of insulin receptor 
substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 
fatty acids and curcumin. J Neurosci 2009, 29:9078-9089.
15.  Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, 
Cherrier MM, Schellenberg GD, Frey WH, 2nd, Craft S: Intranasal insulin 
administration dose-dependently modulates verbal memory and plasma 
amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008, 
13:323-331.
16.  Palozza P, Sgarlata E, Luberto C, Piccioni E, Anti M, Marra G, Armelao F, 
Franceschelli P, Bartoli GM: n-3 fatty acids induce oxidative modifi  cations in 
human erythrocytes depending on dose and duration of dietary 
supplementation. Am J Clin Nutr 1996, 64:297-304.
17.  Allard JP, Kurian R, Aghdassi E, Muggli R, Royall D: Lipid peroxidation during 
n-3 fatty acid and vitamin E supplementation in humans. Lipids 1997, 
32:535-541.
18.  Gonzalez MJ, Gray JI, Schemmel RA, Dugan L Jr, Welsch CW: Lipid 
peroxidation products are elevated in fi  sh oil diets even in the presence of 
added antioxidants. J Nutr 1992, 122:2190-2195.
doi:10.1186/alzrt61
Cite this article as: Frautschy SA, Cole GM: What was lost in translation in 
the DHA trial is whom you should intend to treat. Alzheimer’s Research & 
Therapy 2011, 3:2.
Frautschy and Cole Alzheimer’s Research & Therapy 2011, 3:2 
http://alzres.com/content/3/1/2
Page 4 of 4